Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis

Masayuki Kubo, Tao Sheng Li, Takahiro Kamota, Mako Ohshima, Bungo Shirasawa, Kimikazu Hamano

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: Although secondary lymphedema is a common complication after surgical and radiation therapy for cancer, the treatment options for lymphedema remain limited and largely ineffective. We thus studied the effect of extracorporeal shock wave therapy on promoting lymphangiogenesis and improving secondary lymphedema. Methods: A rabbit ear model of lymphedema was created by disruption of lymphatic vessels. Two weeks after surgery, the lymphedematous ear was treated with or without low-energy shock waves (0.09 mJ/mm2, 200 shots), three times per week for 4 weeks. Results: Western blot analysis showed that the expression of vascular endothelial growth factor (VEGF)-C (1.23-fold, P <.05) and VEGF receptor 3 (VEGFR3; 1.53-fold, P <.05) was significantly increased in the ears treated with shock wave than in the untreated lymphedematous ears. Compared with the control group, shock wave treatment led to a significant decrease in the thickness of lymphedematous ears (3.80 ± 0.25 mm vs 4.54 ± 0.18 mm, P <.05). Immunohistochemistry for VEGFR3 showed the density of lymphatic vessels was significantly increased by shock wave treatment (P <.05). Conclusion: Extracorporeal shock wave therapy promotes lymphangiogenesis and ameliorates secondary lymphedema, suggesting that extracorporeal shock wave therapy may be a novel, feasible, effective, and noninvasive treatment for lymphedema.

Original languageEnglish
Pages (from-to)429-434
Number of pages6
JournalJournal of Vascular Surgery
Volume52
Issue number2
DOIs
Publication statusPublished - Aug 2010
Externally publishedYes

Fingerprint

Lymphangiogenesis
Convulsive Therapy
Lymphedema
Ear
Lymphatic Vessels
Vascular Endothelial Growth Factor Receptor-3
Vascular Endothelial Growth Factor C
Therapeutics
Radiotherapy
Western Blotting
Immunohistochemistry
Rabbits
Control Groups
Neoplasms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis. / Kubo, Masayuki; Li, Tao Sheng; Kamota, Takahiro; Ohshima, Mako; Shirasawa, Bungo; Hamano, Kimikazu.

In: Journal of Vascular Surgery, Vol. 52, No. 2, 08.2010, p. 429-434.

Research output: Contribution to journalArticle

Kubo, Masayuki ; Li, Tao Sheng ; Kamota, Takahiro ; Ohshima, Mako ; Shirasawa, Bungo ; Hamano, Kimikazu. / Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis. In: Journal of Vascular Surgery. 2010 ; Vol. 52, No. 2. pp. 429-434.
@article{0d3fe8817ffd479fbfe0a7e60f373f2e,
title = "Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis",
abstract = "Objective: Although secondary lymphedema is a common complication after surgical and radiation therapy for cancer, the treatment options for lymphedema remain limited and largely ineffective. We thus studied the effect of extracorporeal shock wave therapy on promoting lymphangiogenesis and improving secondary lymphedema. Methods: A rabbit ear model of lymphedema was created by disruption of lymphatic vessels. Two weeks after surgery, the lymphedematous ear was treated with or without low-energy shock waves (0.09 mJ/mm2, 200 shots), three times per week for 4 weeks. Results: Western blot analysis showed that the expression of vascular endothelial growth factor (VEGF)-C (1.23-fold, P <.05) and VEGF receptor 3 (VEGFR3; 1.53-fold, P <.05) was significantly increased in the ears treated with shock wave than in the untreated lymphedematous ears. Compared with the control group, shock wave treatment led to a significant decrease in the thickness of lymphedematous ears (3.80 ± 0.25 mm vs 4.54 ± 0.18 mm, P <.05). Immunohistochemistry for VEGFR3 showed the density of lymphatic vessels was significantly increased by shock wave treatment (P <.05). Conclusion: Extracorporeal shock wave therapy promotes lymphangiogenesis and ameliorates secondary lymphedema, suggesting that extracorporeal shock wave therapy may be a novel, feasible, effective, and noninvasive treatment for lymphedema.",
author = "Masayuki Kubo and Li, {Tao Sheng} and Takahiro Kamota and Mako Ohshima and Bungo Shirasawa and Kimikazu Hamano",
year = "2010",
month = "8",
doi = "10.1016/j.jvs.2010.03.017",
language = "English",
volume = "52",
pages = "429--434",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis

AU - Kubo, Masayuki

AU - Li, Tao Sheng

AU - Kamota, Takahiro

AU - Ohshima, Mako

AU - Shirasawa, Bungo

AU - Hamano, Kimikazu

PY - 2010/8

Y1 - 2010/8

N2 - Objective: Although secondary lymphedema is a common complication after surgical and radiation therapy for cancer, the treatment options for lymphedema remain limited and largely ineffective. We thus studied the effect of extracorporeal shock wave therapy on promoting lymphangiogenesis and improving secondary lymphedema. Methods: A rabbit ear model of lymphedema was created by disruption of lymphatic vessels. Two weeks after surgery, the lymphedematous ear was treated with or without low-energy shock waves (0.09 mJ/mm2, 200 shots), three times per week for 4 weeks. Results: Western blot analysis showed that the expression of vascular endothelial growth factor (VEGF)-C (1.23-fold, P <.05) and VEGF receptor 3 (VEGFR3; 1.53-fold, P <.05) was significantly increased in the ears treated with shock wave than in the untreated lymphedematous ears. Compared with the control group, shock wave treatment led to a significant decrease in the thickness of lymphedematous ears (3.80 ± 0.25 mm vs 4.54 ± 0.18 mm, P <.05). Immunohistochemistry for VEGFR3 showed the density of lymphatic vessels was significantly increased by shock wave treatment (P <.05). Conclusion: Extracorporeal shock wave therapy promotes lymphangiogenesis and ameliorates secondary lymphedema, suggesting that extracorporeal shock wave therapy may be a novel, feasible, effective, and noninvasive treatment for lymphedema.

AB - Objective: Although secondary lymphedema is a common complication after surgical and radiation therapy for cancer, the treatment options for lymphedema remain limited and largely ineffective. We thus studied the effect of extracorporeal shock wave therapy on promoting lymphangiogenesis and improving secondary lymphedema. Methods: A rabbit ear model of lymphedema was created by disruption of lymphatic vessels. Two weeks after surgery, the lymphedematous ear was treated with or without low-energy shock waves (0.09 mJ/mm2, 200 shots), three times per week for 4 weeks. Results: Western blot analysis showed that the expression of vascular endothelial growth factor (VEGF)-C (1.23-fold, P <.05) and VEGF receptor 3 (VEGFR3; 1.53-fold, P <.05) was significantly increased in the ears treated with shock wave than in the untreated lymphedematous ears. Compared with the control group, shock wave treatment led to a significant decrease in the thickness of lymphedematous ears (3.80 ± 0.25 mm vs 4.54 ± 0.18 mm, P <.05). Immunohistochemistry for VEGFR3 showed the density of lymphatic vessels was significantly increased by shock wave treatment (P <.05). Conclusion: Extracorporeal shock wave therapy promotes lymphangiogenesis and ameliorates secondary lymphedema, suggesting that extracorporeal shock wave therapy may be a novel, feasible, effective, and noninvasive treatment for lymphedema.

UR - http://www.scopus.com/inward/record.url?scp=77955502125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955502125&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2010.03.017

DO - 10.1016/j.jvs.2010.03.017

M3 - Article

C2 - 20670777

AN - SCOPUS:77955502125

VL - 52

SP - 429

EP - 434

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 2

ER -